ImmunityBio Sinks 18% as a Sales Miss Outweighs a Phase 3 Win
ImmunityBio fell 17.7% to $7.11 on Monday as a Q3 revenue miss and the first quarter-over-quarter drop in ANKTIVA sales outweighed a Phase 3 win in BCG-naïve bladder cancer. Wick looks at the cash runway, dilution risk and the levels that matter.